Other Pharmacologic Adjuvant Therapy    Collagen-targeting vascular endothelial growth factor improves cardiac performance after myocardial infarction Circulation (2009) 119; 1776-84 J. Zhang, L. Ding, Y. Zhao, W. Sun, B. Chen, H. Lin, X. Wang, L. Zhang, B. Xu and J. Dai B-type natriuretic peptide: a treatment, not a diagnostic marker Heart (2008) 94; 542-4 G. W. Yip Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials Am J Cardiol (2008) 102; 1654-62 J. Wlodarczyk, D. Sullivan and M. Smith Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease Am J Cardiol (2008) 101; 618-24 C. M. Webb, A. G. Elkington, M. M. Kraidly, N. Keenan, D. J. Pennell and P. Collins Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease Am J Cardiol (2008) 102; 192-6 Y. R. van Gestel, S. E. Hoeks, D. D. Sin, C. Simsek, G. M. Welten, O. Schouten, H. Stam, F. W. Mertens, R. T. van Domburg and D. Poldermans Cardiovascular disease and risk factors in Asia: a selected review Circulation (2008) 118; 2702-9 H. Ueshima, A. Sekikawa, K. Miura, T. C. Turin, N. Takashima, Y. Kita, M. Watanabe, A. Kadota, N. Okuda, T. Kadowaki, Y. Nakamura and T. Okamura Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study) Am J Cardiol (2009) 103; 577-82 M. J. Tikkanen, I. Holme, N. B. Cater, M. Szarek, O. Faergeman, J. J. Kastelein, A. G. Olsson, M. L. Larsen, C. Lindahl and T. R. Pedersen Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages Circulation (2009) 119; 28-36 K. Sugamura, S. Sugiyama, T. Nozaki, Y. Matsuzawa, Y. Izumiya, K. Miyata, M. Nakayama, K. Kaikita, T. Obata, M. Takeya and H. Ogawa Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel Am Heart J (2009) 157; 148 e1-5 J. M. Siller-Matula, A. O. Spiel, I. M. Lang, G. Kreiner, G. Christ and B. Jilma A 6 month randomized, double blind, placebo controlled, multi-center trial of high dose atorvastatin on myocardial perfusion abnormalities by positron emission tomography in coronary artery disease Am Heart J (2008) 155; 245-53 S. Sdringola, K. L. Gould, L. G. Zamarka, R. McLain and J. Garner Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance Am J Cardiol (2009) 103; 393-4 J. F. Ruisinger, J. M. Backes, C. A. Gibson and P. M. Moriarty Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event Am J Cardiol (2009) 103; 437-41 R. Rawlings, A. Nohria, P. Y. Liu, J. Donnelly, M. A. Creager, P. Ganz, A. Selwyn and J. K. Liao Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction Am J Cardiol (2009) 103; 461-3 J. C. Quinaglia e Silva, D. B. Munhoz, T. N. Morato, A. Gurgel, A. C. Macedo, P. Sever and A. C. Sposito Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial Am Heart J (2008) 155; 388-94 G. Pedrazzini, E. Santoro, R. Latini, L. Fromm, M. G. Franzosi, T. Mocetti, L. Staszewsky, S. Barlera, G. Tognoni and A. P. Maggioni Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure Circulation (2008) 118; 247-57 D. T. O'Connor, G. Zhu, F. Rao, L. Taupenot, M. M. Fung, M. Das, S. K. Mahata, M. Mahata, L. Wang, K. Zhang, T. A. Greenwood, P. A. Shih, M. G. Cockburn, M. G. Ziegler, M. Stridsberg, N. G. Martin and J. B. Whitfield High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis Am Heart J (2008) 155; 954-8 A. Lotfi, M. J. Schweiger, G. R. Giugliano, S. A. Murphy and C. P. Cannon Hormone therapy and risk of myocardial infarction: a national register study Eur Heart J (2008) 29; 2660-8 E. Lokkegaard, A. H. Andreasen, R. K. Jacobsen, L. H. Nielsen, C. Agger and O. Lidegaard Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention Am J Cardiol (2009) 103; 165-9 E. I. Lev, R. Kornowski, H. Vaknin-Assa, I. Ben-Dor, D. Brosh, I. Teplitsky, S. Fuchs, A. Battler and A. Assali Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon Eur Heart J (2009) 30; 765-72 Y. Kawai, K. Hisamatsu, H. Matsubara, K. Dan, S. Akagi, K. Miyaji, M. Munemasa, Y. Fujimoto, K. F. Kusano and T. Ohe A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE) Am Heart J (2008) 155; 113 e1-8 I. K. Jang, N. J. Weissman, M. H. Picard, M. R. Zile, V. Pettigrew, S. Shen, J. Tatsuno, M. G. Hibberd, D. Tzivoni and F. J. Wackers B-type natriuretic peptide infusions in acute myocardial infarction Heart (2008) 94; 617-22 R. J. Hillock, C. M. Frampton, T. G. Yandle, R. W. Troughton, J. G. Lainchbury and A. M. Richards Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction Eur Heart J (2008) 29; 2265-75 G. Heusch, A. Skyschally, P. Gres, P. van Caster, D. Schilawa and R. Schulz Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort) Am J Cardiol (2009) 103; 381-6 V. Gardette, V. Bongard, J. Dallongeville, D. Arveiler, A. Bingham, J. B. Ruidavets, P. Amouyel, B. Haas, P. Ducimetiere and J. Ferrieres Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function: the Framingham Heart Study Circulation (2009) 119; 1586-91 C. S. Fox, P. Gona, U. Hoffmann, S. A. Porter, C. J. Salton, J. M. Massaro, D. Levy, M. G. Larson, R. B. D'Agostino, Sr., C. J. O'Donnell and W. J. Manning Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells Circulation (2009) 119; 1424-32 R. E. Eid, D. A. Rao, J. Zhou, S. F. Lo, H. Ranjbaran, A. Gallo, S. I. Sokol, S. Pfau, J. S. Pober and G. Tellides Challenging doctors' lifelong habits may be good for their patients: oxygen therapy in acute myocardial infarction Heart (2009) 95; 176-7 N. Danchin and D. Chemla Alpha-linolenic acid and risk of nonfatal acute myocardial infarction Circulation (2008) 118; 339-45 H. Campos, A. Baylin and W. C. Willett Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials) Am J Cardiol (2008) 102; 552-8 E. S. Brilakis, J. A. de Lemos, C. P. Cannon, S. D. Wiviott, S. A. Murphy, D. A. Morrow, M. S. Sabatine, S. Banerjee, M. A. Blazing, R. M. Califf and E. Braunwald Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study Am Heart J (2009) 157; 509-16 e1 Y. Bi, R. Gao, A. Patel, S. Su, W. Gao, D. Hu, D. Huang, L. Kong, W. Qi, Y. Wu, Y. Yang and F. Turnbull Aldosterone and long-term outcome after myocardial infarction: A substudy of the french nationwide Observatoire sur la Prise en charge hospitaliere, l'Evolution a un an et les caRacteristiques de patients presentant un infArctus du myocarde avec ou sans onde Q (OPERA) study Am Heart J (2009) 157; 680-7 F. Beygui, G. Montalescot, E. Vicaut, S. Rouanet, E. Van Belle, C. Baulac, A. Degrandsart and J. Dallongeville Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III) Veldhuisen Am Heart J (2008) 155; 817-22 ) A. M. Belonje, A. A. Voors, W. H. van Gilst, S. D. Anker, R. H. Slart, R. A. Tio, F. Zijlstra and D. J. van Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy Am Heart J (2008) 156; 241-7 S. Bangalore, F. H. Messerli, J. D. Cohen, P. H. Bacher, P. Sleight, G. Mancia, P. Kowey, Q. Zhou, A. Champion and C. J. Pepine